{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-25-000084","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.646610+00:00","generated_at":"2026-05-17T21:14:37.628349+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Myriad Genetics Q2 revenue $213.1M (+1% YoY); raises FY2025 revenue guidance","bullets":["GAAP net loss $330.5M ($3.57/share) includes $316.7M impairment; adjusted EPS $0.05.","Hereditary cancer testing revenue +9% YoY in Oncology; MyRisk with RiskScore volume +14%.","Raised 2025 revenue guidance to $818-828M from $807-823M; adjusted EPS reiterated at $(0.02)-$0.02.","New $200M credit facility with OrbiMed entered July 31; plans to launch ultra-sensitive MRD test H1 2026.","GeneSight revenue down 12% due to UHC coverage discontinuation; prenatal revenue +7%."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-25-000084","json":"https://secwatch.observer/filing/0000899923-25-000084.json","markdown":"https://secwatch.observer/filing/0000899923-25-000084.md","text":"https://secwatch.observer/filing/0000899923-25-000084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992325000084/0000899923-25-000084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992325000084/mygn-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:14:37.628349+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}